CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Hydroxychloroquine Sulfate 200 MGWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug1822 Placebo Wiki 0.04

Correlated MeSH Terms (6)

Name (Synonyms) Correlation
D003333 Coronaviridae Infections NIH 0.35
D014777 Virus Diseases NIH 0.09
D007239 Infection NIH 0.08
D003141 Communicable Diseases NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.04
D018352 Coronavirus Infections NIH 0.03

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There are 2 clinical trials

Clinical Trials

1 Comparative Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19 in Healthcare Personnel

Hydroxychloroquine has been approved by FDA as one of the treatment options for COVID 19.Healthcare personnel are amongst those at highest risk to contract the disease. Several health authorities are now recommending the use of hydroxychloroquine as pre-exposure prophylaxis is in health care personnel. Several studies are on going in this context. However there is a controversy regarding the dosage regimen. This drug has a half life of 22.4 days. In this study we will be comparing three different doses of Hydroxychloroquine and additionally have a control group in order to determine the efficacy of hydroxychloroquine as pre- exposure prophylaxis in healthcare personnel in various doses.

NCT04359537 COVID 19 Drug: Hydroxychloroquine Sulfate 200 MG Other: Placebo

Primary Outcomes

Description: Outcome reported as the percentage of participants in each arm who are COVID-19-free at the end of study treatment

Measure: COVID-19-free survival in experimental arms compared to placebo

Time: 12 weeks

Secondary Outcomes

Description: Outcome reported as the percent of participants in each arm who have a confirmed SARS-CoV-2 infection during study treatment.

Measure: Incidence of confirmed SARS-COV-2 detection

Time: 12 weeks

Description: Outcome reported as the percent of participants in each arm who report COVID-19-related symptoms during study treatment

Measure: Incidence of possible COVID-19 symptoms

Time: 12 weeks

Description: Outcome reported as the percent of participants in each arm who discontinue study medication use for any reason during treatment.

Measure: Incidence of all-cause study medicine discontinuation

Time: 12 weeks

Description: Participants will self-report COVID-19 status on an ordinal scale as follows: No illness (score=1), Illness with outpatient observation (score=2), Hospitalization (or post-hospital discharge) (score=3), Hospitalization with ICU stay (score 4),Death from COVID 19(score=5) Possible scores range from 1-5 with higher scores indicating greater disease severity.

Measure: Ordinal Scale of COVID-19 Disease maximum severity if COVID-19 diagnosed at study end

Time: 12 weeks

Description: Outcome reported as the percent of participants in each arm who are hospitalized or expire due to COVID-19 during study treatment.

Measure: Incidence of Hospitalization for COVID-19 or death

Time: 12 weeks

Description: Outcome reported as the percent of participants experiencing any possible adverse events from Hydroxychloroquine

Measure: Incidence of study medication-related adverse events

Time: 12 weeks

2 PROphylaxis for paTiEnts at Risk of COVID-19 infecTion (PROTECT): a Basket Trial of Prophylactic Interventions Amongst At-risk Patients

The PROTECT open-label randomised basket trial will assess the effectiveness of hydroxychloroquine (HCQ) as chemoprophylaxis against COVID-19 in multiple vulnerable populations in the United Kingdom.

NCT04389359 COVID-19 Drug: Hydroxychloroquine Sulfate 200 MG
MeSH:Infection

Primary Outcomes

Description: The primary outcome for PROTECT is the time to confirmed COVID-19 infection from the date of randomisation. This will be captured via linkage with PHE or by direct reporting by sites.

Measure: Time to confirmed diagnosis of COVID-19

Time: To study completion, average 6 months

Secondary Outcomes

Description: Death from any cause

Measure: All-cause mortality

Time: To study completion, average 6 months

Description: Severity will be assessed by requirement for hospitalisation, HDU/ICU admission or death and Length of inpatient stay.

Measure: Severity of COVID-19 disease

Time: To study completion, average 6 months

Description: Acute respiratory distress syndrome, viral pneumonitis, myocarditis/myocardial injury, acute kidney injury.

Measure: Incidence of COVID-19 complications

Time: To study completion, average 6 months

No related HPO nodes (Using clinical trials)